Alnylam CEO Touts Advances with Lipid, Conjugate Delivery Approaches

During a presentation to investors last week, CEO John Maraganore highlighted the company's collaborations with Massachusetts Institute of Technology and AlCana, but notably made no mention of partner Tekmira Pharmaceuticals, which sued Alnylam earlier in the year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.